Table 2.
The association between variables and LVRR at univariable and multivariable logistic regression.
| Univariable Logistic Regression | Multivariable Logistic Regression | |||
|---|---|---|---|---|
| Characteristics | Crude OR (95%CI) | p-Value | Adjusted OR (95%CI) | p-Value |
| Age | 0.99 (0.97–1.01) | 0.098 | ||
| Gender | 0.9 (0.54–1.52) | 0.704 | ||
| BMI | 1.07 (1.03–1.12) | 0.003 | 1.07 (1.01–1.14) | 0.026 |
| NYHA III/IV | 0.67 (0.4–1.11) | 0.118 | ||
| SBP | 1.03 (1.01–1.04) | <0.001 | 1.02 (1.01–1.04) | 0.035 |
| T2DM | 0.46 (0.25–0.86) | 0.015 | 0.30 (0.14–0.65) | 0.002 |
| AF | 0.75 (0.45–1.25) | 0.272 | ||
| QRS duration | 0.90 (0.82–0.98) | 0.015 | 0.92 (0.84–1.02) | 0.124 |
| LBBB | 0.66 (0.31–1.41) | 0.282 | ||
| LVEF | 1.01 (0.99–1.04) | 0.325 | ||
| LVEDD | 0.97 (0.95–1.01) | 0.024 | 0.98 (0.95–1.01) | 0.167 |
| RVD | 0.97 (0.93–1.01) | 0.147 | ||
| Hemoglobin | 1.02 (1.01–1.03) | 0.009 | ||
| log Big ET-1 | 0.67 (0.55–0.83) | <0.001 | 0.70 (0.55–0.89) | 0.003 |
| log NT-Pro-BNP | 0.84 (0.74–0.96) | 0.012 | ||
| log Scr | 0.76 (0.45–1.29) | 0.304 | ||
| ACEI/ARB | 2.63 (1.40–4.93) | 0.003 | 2.30 (1.02–5.21) | 0.045 |
| β-blocker | 4.62 (0.57–37.35) | 0.151 | ||
| MRA | 2.59 (0.55–12.17) | 0.228 | ||
Variables that were significantly associated with LVRR (p < 0.1) in the univariable analysis were included in the multivariable stepwise regression in backward and forward directions guided by AIC. Independent predictors for LVRR (p < 0.05 in multivariable model) are shown in bold. The levels of biomarkers such as Big ET-1, NT-pro-BNP and serum creatine were log2 transformed. SBP: systolic blood pressure; BMI: body mass index; T2DM: Type 2 diabetes mellitus; NYHA, New York Heart Association; AF: atrial fibrillation; LBBB: left bundle branch block; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; RVD: right ventricular diameter; Scr: serum creatine; Big ET-1: Big endothelin-1; NT-Pro BNP: N-terminal Pro Brain natriuretic peptide; ACEI: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; MRA: mineralocorticoid receptor antagonists.